Maraviroc.

Maraviroc. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Maraviroc. Abstract Text:

Natalie J Carter,Gillian M Keating,Natalie J Carter,Gillian M Keating,Natalie J Carter,Gillian M Keating,Natalie J Carter,Gillian M Keating,

Maraviroc is a specific, slowly reversible, noncompetitive, small-molecule antagonist of the CCR5 chemokine receptor, which also serves as an HIV-1 coreceptor. By acting as an antagonist at the CCR5 coreceptor, maraviroc inhibits HIV-1 from entering host cells. Clinical data for maraviroc are available from two large, well designed, ongoing phase IIb/III trials (MOTIVATE-1 and MOTIVATE-2) conducted in patients infected with R5-tropic HIV-1 who had previously received at least one agent from three of the four classes of antiretroviral drugs and/or were triple-class resistant. According to 24-week interim results of the MOTIVATE-1 and -2 trials, a significantly greater reduction in viral load occurred in patients receiving maraviroc 150 or 300mg (depending on optimised background therapy [OBT]) twice daily plus OBT compared with placebo plus OBT. This significant difference was maintained at 48 weeks in MOTIVATE-1. In the MOTIVATE-1 and -2 trials, a significantly greater proportion of patients receiving maraviroc plus OBT achieved an HIV-1 RNA level <400 and <50 copies/mL compared with those receiving placebo plus OBT. In addition, the CD4+ cell count was increased to a significantly greater extent with maraviroc plus OBT compared with placebo plus OBT. The 48-week results of MOTIVATE-1 also report a significant difference in favour of maraviroc for all these endpoints. In general, maraviroc at dosages of up to 300mg twice daily was well tolerated in treatment-experienced patients infected with R5-tropic HIV-1.

Maraviroc. Publishing Authors By Initials

NJ Carter,GM Keating,NJ Carter,GM Keating,NJ Carter,GM Keating,NJ Carter,GM Keating,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Maraviroc. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Drugs

VOLUME: 67

Page Numbers: 2277-88; discussion 2289-90

Journal Abbreviation: Drugs

ISSN: 0012-6667

DAY: 11

MONTH: 10

YEAR: 2007

Maraviroc. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7600076

Maraviroc. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Maraviroc. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Maraviroc.

AFFILIATION: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Maraviroc Related Publications

• Activin-betaA signaling is required for zebrafish fin regeneration.
• Campuses of the LACC.
• Celecoxib : a review of its use in the management of arthritis and acute pain.
• Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
• Colesevelam: a review of its use in hypercholesterolemia.
• Computing van der Waals energies in the context of the rotamer approximation.
• Coupling molecular beacons to barcoded metal nanowires for multiplexed, sealed chamber DNA bioassays.
• Coverage and prior authorization of psychotropic drugs under Medicare Part D.
• Deferasirox : a review of its use in the management of transfusional chronic iron overload.
• Differences in hospice care between home and institutional settings.
• Distance-dependent emission from dye-labeled oligonucleotides on striped Au/Ag nanowires: effect of secondary structure and hybridization efficiency.
• Dr. Tom Lawrence: a life in chiropractic.
• E14 Therapy for CLL: current approach, future trends.
• Gene expression analysis of zebrafish heart regeneration.
• Maraviroc.
• Metallic barcodes for multiplexed bioassays.
• Methods for simulating the dynamics of complex biological processes.
• Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.
• Monoclonal antibodies in chronic lymphocytic leukemia.
• On-beam synchrony in the cerebellum as the mechanism for the timing and coordination of movement.
• One size doesn't fit all.
• Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair.
• Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness.
• Revision anterior cruciate ligament reconstruction: timing of surgery and the incidence of meniscal tears and degenerative change.
• Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
• Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
• Silica-coated, Au/Ag striped nanowires for bioanalysis.
• The Homewood influence in Canada and beyond.
• Transcriptional profiling of caudal fin regeneration in zebrafish.
• Using performance data to identify preferred hospitals.